{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:28:50Z","timestamp":1789180130700,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019139","name":"Life Sciences, University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ajo.2025.04.032","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T02:24:22Z","timestamp":1746239062000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Sustained Suppression of VEGF for Treatment of Retinal and Choroidal Vascular Diseases"],"prefix":"10.1016","volume":"277","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2531-8229","authenticated-orcid":false,"given":"Peter A.","family":"Campochiaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2025.04.032_bib0001","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajo.2025.04.032_bib0002","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1073\/pnas.92.3.905","article-title":"Vascular endothelial growth factor\/vascular permeability factor expression in a mouse model of retinal neovascularization","volume":"92","author":"Pierce","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ajo.2025.04.032_bib0003","doi-asserted-by":"crossref","first-page":"10457","DOI":"10.1073\/pnas.92.23.10457","article-title":"Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins","volume":"92","author":"Aiello","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ajo.2025.04.032_bib0004","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ajo.2025.04.032_bib0005","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ajo.2025.04.032_bib0006","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ajo.2025.04.032_bib0007","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","article-title":"Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study","volume":"121","author":"Heier","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.032_bib0008","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.032_bib0009","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.ophtha.2009.04.023","article-title":"Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study","volume":"116","author":"Nguyen","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.032_bib0010","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.032_bib0011","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.032_bib0012","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.032_bib0013","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Efficacy and safety of ranibizumab in the treatment of macular edema secondary to central retinal vein occlusion: 6-month results of the phase III CRUISE study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.032_bib0014","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: 6-month primary endpoint results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.032_bib0015","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ajo.2012.09.026","article-title":"Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS Study","volume":"155","author":"Brown","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.04.032_bib0016","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ophtha.2014.08.031","article-title":"Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study","volume":"122","author":"Campochiaro","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.032_bib0017","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1001\/jama.2017.4568","article-title":"Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial","volume":"317","author":"Scott","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ajo.2025.04.032_bib0018","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.04.032_bib0019","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","article-title":"Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS registry","volume":"125","author":"Rao","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.032_bib0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","article-title":"Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49,485 eyes","volume":"4","author":"Ciulla","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ajo.2025.04.032_bib0021","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28,658 patient eyes","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.04.032_bib0022","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/09286586.2020.1792937","article-title":"Real-world visual and neovascularization outcomes from anti-VEGF in central retinal vein occlusion","volume":"28","author":"Hogg","year":"2021","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.ajo.2025.04.032_bib0023","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.95530","article-title":"Reversible retinal vessel closure from VEGF-induced leukocyte plugging","volume":"2","author":"Liu","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.ajo.2025.04.032_bib0024","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.ophtha.2012.09.032","article-title":"Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion","volume":"120","author":"Campochiaro","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.032_bib0025","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ophtha.2014.03.021","article-title":"Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema","volume":"121","author":"Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.032_bib0026","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.oret.2019.07.011","article-title":"Intravitreal aflibercept for retinal nonperfusion in proliferative diabetic retinopathy outcomes from the randomized RECOVERY trial","volume":"3","author":"Wykoff","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ajo.2025.04.032_bib0027","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1172\/JCI129862","article-title":"Anti-VEGF therapy: higher potency and long-lasting antagonism are not necessarily better","volume":"129","author":"Usui-Ouchi","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajo.2025.04.032_bib0028","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1172\/JCI129861","article-title":"Low risk to retina from sustained suppression of VEGF","volume":"129","author":"Campochiaro","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajo.2025.04.032_bib0029","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1172\/JCI65157","article-title":"Targeted deletion of Vegfa in adult mice induces vision loss","volume":"122","author":"Kurihara","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajo.2025.04.032_bib0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jcp.21445","article-title":"Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels","volume":"217","author":"Ueno","year":"2008","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ajo.2025.04.032_bib0031","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials","volume":"121","author":"Grunwald","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.032_bib0032","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2-year findings of the IVAN randomized controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2025.04.032_bib0033","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","article-title":"Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.032_bib0034","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":"Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.032_bib0035","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","article-title":"Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN Study","volume":"121","author":"Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.032_bib0036","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajo.2014.09.012","article-title":"Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes","volume":"159","author":"Channa","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.04.032_bib0037","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ophtha.2018.07.013","article-title":"Intralesional macular atrophy in anti-vascular endothelial growth factor therapy for age-related macular degeneration in the IVAN trial","volume":"126","author":"Bailey","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.032_bib0038","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.oret.2019.09.016","article-title":"Type 1 choroidal neovascularization is associated with reduced localized progression of atrophy in age-related macular degeneration","volume":"4","author":"Pfau","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ajo.2025.04.032_bib0039","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1167\/iovs.63.11.4","article-title":"The fovea-protective impact of double-layer sign in eyes with foveal-sparing geographic atrophy and age-related macular degeneration","volume":"63","author":"Fukuyama","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.04.032_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2024.11.009","article-title":"Refillable drug reservoirs for retinal vascular diseases","author":"Clark","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.04.032_bib0040","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.oret.2024.05.021","article-title":"Interim results of the phase III Portal extension trial of the port delivery system with ranibizumab in neovascular age-related macular degeneration","volume":"9","author":"Campochiaro","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ajo.2025.04.032_bib0041","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","article-title":"Suprachoroidal drug delivery to the back of the eye using hollow needles","volume":"28","author":"Patel","year":"2011","journal-title":"Pharm Res"},{"key":"10.1016\/j.ajo.2025.04.032_bib0042","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1167\/iovs.12-9872","article-title":"Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye","volume":"53","author":"Patel","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.04.032_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2025.04.020","article-title":"Suprachoroidal drug delivery for VEGF suppression in wet AMD and other diseases with choroidal neovascularization","author":"Chiang","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.04.032_bib0043","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","article-title":"Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial","volume":"127","author":"Yeh","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.04.032_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100586","article-title":"Safety and tolerability of suprachoroidal axitinib injectable suspension, for neovascular age-related macular degeneration; phase I\/IIa open-label, dose-escalation trial","volume":"5","author":"Barakat","year":"2025","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.ajo.2025.04.032_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2024.12.010","article-title":"Suprachoroidal delivery of viral and nonviral vectors for treatment of retinal and choroidal vascular diseases","author":"Lim","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.04.032_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2025.03.016","article-title":"Can sustained suppression of VEGF be achieved by topical delivery?","author":"Bingaman","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.04.032_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2024.12.002","article-title":"Subretinal gene therapy for treatment of retinal and choroidal vascular diseases","author":"Khanani","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.04.032_bib0045","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2025.04.032_bib0046","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/mt.2009.181","article-title":"Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous","volume":"17","author":"Dalkara","year":"1998","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajo.2025.04.032_bib0047","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005708","article-title":"In vivo\u2013directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ajo.2025.04.032_bib0048","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41467-020-14340-x","article-title":"Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles","volume":"11","author":"Tsujinaka","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajo.2025.04.032_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2024.10.031","article-title":"Home optical coherence tomography and sustained delivery approaches: a perfect marriage","author":"Holekamp","year":"2024","journal-title":"Am J Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425002193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425002193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T13:17:54Z","timestamp":1754918274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939425002193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":54,"alternative-id":["S0002939425002193"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.04.032","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained Suppression of VEGF for Treatment of Retinal and Choroidal Vascular Diseases","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.04.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}